MedTrace Logo

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

NCT02247310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 498

Last updated 2017-11-07

No results posted yet for this study

Summary

Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is important. The data storage capabilities of the BETACONNECT device, including the automated recording of injections, will facilitate the collection of reliable data on patient's injection behavior and adherence, which should be unaffected by recall bias or reporting bias.

To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using this device for 24 weeks. The study will take place in a real-life setting in Neurology centers across Europe.

Conditions

  • Multiple Sclerosis, Relapsing Remitting

Interventions

DRUG

Interferon beta-1b (Betaferon®, BAY 86-5046)

Patients will be treated with Betaferon

DEVICE

BETACONNECT

Auto-injector device to support the injection of Betaferon

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-20
Primary Completion
2016-07-19
Completion
2016-11-08

Countries

  • Austria
  • Belgium
  • Bosnia and Herzegovina
  • Croatia
  • Czechia
  • France
  • Greece
  • Hungary
  • Italy
  • Spain
  • Switzerland

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02247310 on ClinicalTrials.gov